Toegang tot weesgeneesmiddelen
Datum: 22-02-2017 - 23-02-2017
Take part in multi-stakeholder debate on access to therapie
Improving patients’ access to rare disease therapies has long been a priority for EURORDIS and its member organisations throughout Europe.
In February 2016, the first in a series of symposia took place to discuss this crucial topic. A unique combination of nearly 300 patient advocates, academics, policymakers, industry representatives, payers and health technology assessment (HTA) bodies came together to discuss the current state of play and how to shape a more effective way to improve patients’ access.
The symposium addressed a crucial bottleneck in making rare disease therapies accessible across Europe; new medicines are being developed, but scientific innovation cannot be disconnected from access to medicines. If an innovative medicine is approved but does not reach patients because of pricing or reimbursement considerations, it fails in its primary objective. Read the conclusions document of the February 2016 symposium to learn more about the perspectives of the various stakeholder groups that participated.
Register for the next symposium!
The second symposium in this series will take place on 22 – 23 February 2017 in Brussels.
Take part in truly multi-stakeholder discussions with representatives from patient organisations, industry, academic and research institutions, as well as policymakers, payers and representatives from HTA authorities. All participants will be encouraged to speak openly about the issues that concern them.